ResultsIQ › Latest results › Amanta Healthcare Limited
Amanta Healthcare Limited Q2 FY27 results deck summary
NSE: AMANTA · BSE: 544502
Results deck of 4 Nov 2026, summarised by AI from the filing.
Q2 FY27 revenue ₹83.13 cr, up 17.3% YoY, with SteriPort Line 3 live and ~₹60 Cr revenue expected from it in FY27.
Key takeaways
- Q2 FY27 results Revenue ₹83.13 cr, up 17.3% YoY, EBITDA ₹17.95 cr at 21.6% margin and PAT ₹4.86 cr at 6% margin.
- Two-year aim Management targets 20%+ revenue CAGR and 25%+ EBITDA margin over two years.
- SteriPort Line 3 Line 3 was commissioned in the first week of September 2026, lifting SteriPort capacity 75% to 11.6 Cr bottles.
- Line 3 revenue ~₹60 Cr revenue expected from Line 3 in FY27, rising to ₹110–120 Cr a year at optimal utilisation.
- Cash position Cash & cash equivalents fell to ₹2 cr at H1 FY27 from ₹81 cr at FY26, with current borrowings at ₹147 cr.
Amanta Healthcare Limited Q2 FY27 results
As filed: Revenue ₹83.1 cr (+17% year on year), EBITDA ₹17.2 cr (+15% year on year), PAT ₹4.9 cr (+300% year on year), EBITDA margin 20.7% (−45 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹68.8 cr (+6% year on year), EBITDA ₹14.5 cr (−3% year on year), PAT ₹3.3 cr (−17% year on year), EBITDA margin 21.1% (−194 bps). Score 28 of 100, Below trend. EBITDA margin fell 194 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 11% from last quarter. Share price after the results: +12.2% in 30 days (Nifty 500: −2.0%).
- Q4 FY26: Revenue ₹77.0 cr, EBITDA ₹15.0 cr, PAT ₹5.5 cr, EBITDA margin 19.4%. Not scored. No result for the same quarter last year. Share price after the results: +18.4% in 30 days (Nifty 500: +3.3%).
- Q3 FY26: Revenue ₹74.5 cr, EBITDA ₹15.4 cr, PAT ₹4.6 cr, EBITDA margin 20.6%. Not scored. No result for the same quarter last year. Share price after the results: −7.2% in 30 days (Nifty 500: −7.5%).
- Q2 FY26: Revenue ₹71.0 cr, EBITDA ₹15.0 cr, PAT ₹1.0 cr, EBITDA margin 21.1%. Not scored. No result for the same quarter last year. Share price after the results: −15.9% in 30 days (Nifty 500: −0.6%).
- Q1 FY26: Revenue ₹65.0 cr, EBITDA ₹15.0 cr, PAT ₹4.0 cr, EBITDA margin 23.1%. Not scored. No result for the same quarter last year. Share price after the results: −9.5% in 28 days (Nifty 500: +4.3%).
Past price moves after results do not indicate future moves. Not a recommendation.
Amanta Healthcare Limited earnings call, investor presentation and press release summaries
Figures from the company's filings with NSE and BSE. Not investment advice.